p < 0.005), higher stroke volume index (27 ± 2 vs 20 ± 1 mI/m2, p < 0.005) and higher stroke work Index (32 ± 4 vs 19 ± 2 g-m/m2, p < 0.01) than late nonresponders. There were no significant differences in the acute response to vasodilators between the two groups.
We conclude that (1) a substantial portion of patients with refractory congestive heart failure either do not have a beneficial response to vasodilator therapy or discontinue it because of side effects; (2) about half of the patients who are maintained on chronic vasodilator therapy (or about one-fourth of the patients in whom therapy is initiated) had sustained clinical benefit; and (3) the initial hemodynamics, but not the clinical variables, are predictive of late mortality and late clinical response. Patients with evidence of more severe left ventricular dysfunction have an unfavorable course.
VASODILATOR drugs improve cardiac performance in patients with chronic congestive heart failure.1'~' Hydralazine, whose predominant effect is arteriolar vasodilation, has been shown to increase cardiac output in these patients.2 8 [8] [9] [10] [11] When hydralazine is combined with long-acting nitrates, left ventricular filling pressure is also reduced." 10 Although combined vasodilator therapy acutely improves hemodynamics, the long-term results of such therapy are uncertain in patients with chronic heart failure, who have a poor prognosis.12 14 We undertook this study to heart failure. Sixty-two percent of the patients were referred to our institution and 38% were admitted from the emergency room or cardiology clinic for further management of congestive heart failure. All patients were clinically stable at the time of initial study. There were 21 males and 13 females, mean age 52 1,1 years (± SEM). Twenty-one patients were in NYHA functional class IV and 13 patients were in class III. Congestive heart failure was caused by old myocardial infarction in 17 patients (50%), cardiomyopathy in nine patients (26%) and late heart failure after valve replacement in eight patients (24%). Previous myocardial infarction was defined by clinical, enzymatic and electrocardiographic criteria for transmnural infarction.'5 Prosthetic valve malfunction and primary valvular disease were excluded by cardiac catheterization and angiography in 12 patients.
Hemodynamic Measurements
Right atrial, pulmonary artery and pulmonary artery wedge pressures were measured in all patients by right-heart catheterization using a triple-lumen, balloon-tipped thermodilution catheter (Swan-Ganz Catheter, Edwards Laboratories). Systemic arterial pressure was measured directly using a small polyethylene catheter introduced into the brachial artery. Mean pressures were determined electronically. Cardiac output was measured in triplicate by the thermodilution technique using an analog computer (9520 Thermodilution Computer, Edwards Laboratories) and the mean value was used.
Derived hemodynamic variables were calculated as follows: cardiac index (1/min/M2) = cardiac output/ body surface area; stroke volume index (SVI) (m1/mi2) = cardiac index/heart rate; stroke work index (g-m/ m2) = (mean systolic pressure [MSP] -mean pulmonary artery wedge pressure) X SVI X 0.0136, where MSP was estimated from the formula D + 2(S -D)/3; systemic vascular resistance (dyn-sec-cm 5) = 80(mean arterial pressure -mean right atrial pressure)/cardiac output.
Vasodilator Protocol
Digitalis and diuretic preparations were continued without change during the acute drug trial. Control measurements of pressures and cardiac output were performed at 30-minute intervals until a stable baseline was reached. Hydralazine was then administered orally at an initial dose of 50-75 mg. The dosage was increased every 3-4 hours in 25-mg increments, provided that heart rate did not increase by . 15 
Follow-up
The latest clinical follow-up of living patients was at least 6 months after the initial drug trial. Complete follow-up was obtained in 32 patients by regular clinic visits and examination by one of the authors or in two cases by telephone contact with both the patient and his primary physician. Patients who died within 6 months while receiving vasodilator therapy were included in the analysis; follow-up time was considered to be the interval between the initiation of therapy and the terminal event. The response to therapy in such patients was determined by functional class at the time of the last clinic follow-up visit.
Late clinical response was assessed according to NYHA functional classification. A patient was considered to be a late responder if he was in functional class I or II and a late nonresponder if he was fuinctional class III or IV.
Statistical analysis of the results was performed using the two-tailed t tests for paired and unpaired values and chi-square analysis.`6 Actuarially determined survival was evaluated using methods previously described.17
Results

Acute Hemodynamic Response
Optimal therapy with hydralazine failed to increase stroke volume index by 20% in seven of the 34 patients (21%) ( fig. I ). Therapy was limited by an increase in heart rate in five patients, by a reduction in arterial pressure from 120/64 to 86/44 mm Hg in one patient with coronary artery disease, and by the onset of (mean ± SEM) (p < 0.05) due to an increase in heart rate from 88 ± 2 to 104 ± 3 beats/min (p < 0.001).
Hydralazine increased stroke volume index by more than 20% in 27 patients (79%). Twelve (44%) of these patients required additional long-acting nitrates to decrease mean pulmonary artery wedge pressure. In this group vasodilator therapy reduced mean arterial pressure from 89 ± 3 to 85 ± 3 mm Hg (NS) and increased heart rate from 86 ± 2 to 93 ± 3 beats/min (p < 0.005). Mean pulmonary artery wedge pressure was reduced from 27 ± 2 to 20 i 2 mm Hg (p Hydralazine was discontinued before hospital discharge because of side effects in three of these 27 patients ( fig. l) . One patient developed a drug fever, one had intolerable anorexia and nausea, and one developed angina secondary to drug-induced tachycardia.
Long-term Follow-up Twenty-four patients were discharged from the hospital and continued to receive vasodilator therapy. These patients were followed for 10 ± 8 months (range 1-26 months) ( fig. 1 ). The mean daily dose of hydralazine was 243 ± 43 mg (range 150450 mg). Twelve patients (50%) required additional long-acting nitrates: nine received sublingual isosorbide dinitrate (mean 54 ± 6 mg/day) and three received nitroglycerin ointment (mean 4 inches every 6 hours). Hydralazine therapy was subsequently discontinued in five patients because of late side effects ( fig. 1) . A lupus syndrome developed after 4 months of therapy in one patient who was receiving 300 mg/day, drug fever after 1 month in another and intolerable anorexia and nausea within 2 weeks in three patients.
The 15 patients who were not maintained on longterm vasodilator therapy because of an equivocal acute hemodynamic response or side effects were followed for 10 ± 2 months. All patients remained markedly limited by symptoms and all were considered to be in NYHA class III or IV on follow-up. The actuarial curve ( fig. 2) shows that 1-year survival was 69 ± 9% in this group.
Of the 19 patients who tolerated chronic vasodilator therapy, nine (47%) showed sustained improvement, to functional class I or II, after a follow-up of 12 ± 2 months ( fig. 1 ). The doses of vasodilators and diuretics were unchanged in this group of patients during the follow-up period. Two of the late responders recently relapsed to functional class III after 9 and 11 months of therapy; one of these two patients subse- fig. 3 ). There was no significant difference between late responders and late nonresponders with respect to initial heart rate, mean arterial pressure, cardiac index and systemic vascular resistance (table 2) .
Comparison of the magnitude of change in pressures and cardiac output in response to vasodilator therapy revealed no significant differences between the two groups for any variable. Measurements performed after the optimal dose of hydralazine and nitrates showed that late responders had significantly higher stroke volume index (p < 0.05) and lower right atrial pressure (p < 0.05) than did late nonresponders (table 2) .
The initial hemodynamic variables for the nine late responders were compared with those of the seven patients who failed to show an adequate hemodynamic response to oral hydralazine. There was no significant difference between the groups for any of the variables measured.
Discussion
These data show that almost half the patients with refractory heart failure who respond acutely to vasodilators and are able to tolerate long-term therapy experience substantial clinical improvement. The likelihood of clinical improvement as well as subsequent mortality can be predicted by initial hemodynamic values. However, 44% of our patients either failed to respond to therapy acutely or were forced to discontinue vasodilators because of side effects. Mortality in these patients was considerable, whether long-term vasodilator therapy was undertaken or not.
Hemodynamic monitoring was necessary to determine the vasodilator regimen that resulted in optimal unloading conditions. The dose of hydralazine that produced the most beneficial hemodynamic response ranged from 150-450 mg. Such variability in dosage requirement was reported by Packer et al. '8 In addition, only 12 of 24 (50%) of our patients required longacting nitrates to reduce pulmonary artery wedge pressure below 20 mm Hg. The use of venodilators in patients whose left ventricular filling pressure is not elevated has been shown to reduce cardiac output by the Starling mechanism."'
The acute changes in cardiac performance in our patients after treatment with hydralazine and nitrates are similar to those previously reported.2 8,1}11 However, the 21% incidence of an equivocal hemodynamic response to hydralazine exceeds that noted in the past. Had we used changes in cardiac index rather than stroke volume index to define a favorable response, three of the seven nonresponders would have had a favorable response to therapy. Because the increase in cardiac index in these patients was due to a substantial increase in heart rate rather than to an improvement in left ventricular performance, hydralazine was discontinued. Although little information is available about the long-term effects of changes in heart rate in patients with congestive heart failure, a chronic increase in heart rate could be deleterious, particularly to patients with underlying coronary artery disease. Hydralazine was discontinued because of intolerable side effects in eight of our 34 patients (24%). The most common side effects were gastrointestinal; anorexia, nausea and vomiting were the major symptoms. The high incidence of side effects in this study is probably related to the relatively high dose of hydralazine (243 ± 43 mg/day) required in our patients and the fact that gastrointestinal symptoms are more likely to occur because of splanchnic congestion in patients with heart failure. Important additional side effects seen in this series were drug fever, the lupus syndrome and tachycardia-induced angina. No patient developed clinically significant orthostatic hypotension or a peripheral neuropathy. The relatively high incidence of side effects with hydralazine has been reported. 20' 21 In our series, 47% of patients who increased stroke volume acutely and tolerated long-term vasodilator therapy (26% of the entire population) had sustained symptomatic relief. One of the nine late responders had no symptoms of heart failure 26 months after the initiation of therapy and is considered to be in NYHA functional class I. Although late responders have experienced relief of symptoms for up to 26 months, how long this improvement can be maintained is uncertain. The fact that two of the late responders who were in class II recently relapsed back into class III suggests a gradual attrition over time.
Although overall mortality for the 19 patients who received long-term therapy was poor (actuarial survival of 56% at 12 months), improvement in functional class was associated with relatively good survival; only one of the late responders had died during a follow-up 6 months, five of the nine had improved symptomatically and four remained clinically unchanged; two of the nine patients died during the follow-up period. In these studies the total number of patients with refractory heart failure in whom vasodilator therapy had been attempted was not stated.
In our series, late responders could not be separated from late nonresponders on the basis of age, sex, functional class, etiology of heart failure or clinical events leading to hospitalization. Also, both groups had a similar acute response to therapy. The latter finding may be influenced by the fact that only patients who increased stroke volume by at least 20% were included in the analysis and there was little chance for hemodynamic differences between the groups to emerge. However, our data show that late nonresponders had higher initial right atrial and pulmonary artery wedge pressures and lower stroke work and stroke volume indexes than did the late responders. It is likely that the more severe hemodynamic abnormalities noted in the late nonresponders were the result of more severe underlying left ventricular dysfunction. Thus Our study shows that patients with advanced congestive heart failure have a poor prognosis whether they are maintained on vasodilators or conventional therapy alone. About half of the patients who had a beneficial acute response to vasodilator drugs and who tolerated therapy experience significant symptomatic relief with long-term vasodilator therapy. Conversely, about half the patients who showed a beneficial hemodynamic response to hydralazine and who tolerated chronic therapy had no change in functional class, indicating that early hemodynamic response is not necessarily translated to long-term clinical improvement. The severity of underlying myocardial dysfunction appears to have strong influence on the clinical response to vasodilator drugs and is a potent predictor of mortality.
